Anxiety DisordersObsessive-Compulsive Disorder (OCD)Substance Use Disorders (SUD)SchizophreniaSet & SettingEquity and EthicsMedicinal Chemistry & Drug Development

Human hallucinogen research: guidelines for safety

This paper reviews the psychological risks of human research with classical hallucinogens and provides practical safety guidelines—rigorous screening, preparatory rapport, a controlled physical setting and interpersonal support from at least two monitors—to minimise acute distress (“bad trips”) and the risk of prolonged psychosis. The authors conclude that persisting adverse reactions are rare when these safeguards are followed, allowing ethically conducted research that may advance psychiatric treatment and basic science.

Authors

  • Roland Griffiths
  • Matthew Johnson
  • William Richards

Published

Journal of Psychopharmacology
meta Study

Abstract

There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the study site. Less common are prolonged psychoses triggered by hallucinogens. Safeguards against these risks include the exclusion of volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, establishing trust and rapport between session monitors and volunteer before the session, careful volunteer preparation, a safe physical session environment and interpersonal support from at least two study monitors during the session. Investigators should probe for the relatively rare hallucinogen persisting perception disorder in follow-up contact. Persisting adverse reactions are rare when research is conducted along these guidelines. Incautious research may jeopardize participant safety and future research. However, carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.

Available with Blossom Pro

Research Summary of 'Human hallucinogen research: guidelines for safety'

Introduction

After decades of near-dormancy, human research with classical hallucinogens has been renewed, producing studies that probe basic neuroscience, perception, pharmacokinetics, and potential clinical applications (for example, anxiety in advanced cancer and obsessive–compulsive disorder). Johnson and colleagues place this revival in historical context: early widespread research in the 1950s–1960s was followed by sensationalism, political restriction and a long hiatus, and contemporary investigators therefore face particular scientific and sociopolitical sensitivities when designing human-administered hallucinogen studies. This paper sets out to describe the unique risks of administering high doses of classical hallucinogens and to propose practical guidelines to minimise those risks. The authors focus on safety-related recommendations for high-dose administration (illustratively defined as ≥25 mg psilocybin or 200 µg LSD), addressing volunteer selection, study personnel and training, physical environment, volunteer preparation, session conduct, and post-session follow-up. They also review relevant historical and clinical literature to justify and illustrate the proposed safeguards.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

See Pro PlansAlready have an account? Sign in
Open PDF in new tab

Study Details

References (24)

Papers cited by this study that are also in Blossom

Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans

Bonson, K. R. · Neuropsychopharmacology (1996)

112 cited
Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)

Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)

Do hallucinogens cause residual neuropsychological toxicity?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (1999)

71 cited
Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)

204 cited
Psychological and cognitive effects of long-term peyote use among Native Americans

Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Biological Psychiatry (2005)

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study

Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)

181 cited
LSD in the supportive care of the terminally ill cancer patient

Kurland, A. A. · Journal of Psychoactive Drugs (1985)

Show all 24 references
Reactions to psilocybin administered in a supportive environment

Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)

A clinical study of LSD treatment in alcoholism

Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)

158 cited
Treatment of alcoholism using psychedelic drugs: a review of the program of research

Mangini, M. · Journal of Psychoactive Drugs (2011)

The use of psychedelic agents with autistic schizophrenic children

Mogar, R. E., Aldrich, R. W. · Psychedelic Review (1971)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers

Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)

LSD-assisted psychotherapy and the human encounter with death

Goodman, L. E., Grof, S., Kurland, A. A. et al. · Journal of Transpersonal Psychology (1972)

Experimental Psychiatry. V - Psilocybine, a New Psychotogenic Drug

Rinkel, M., Atwell, C. R., DiMascio, A. et al. · New England Journal of Medicine (1960)

Can psychedelics have a role in psychiatry once again?

Sessa, B. · British Journal of Psychiatry (2018)

96 cited
Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans

Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)

118 cited
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis

Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)

Effects of psilocybin on time perception and temporal control of behaviour in humans

Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)

212 cited

Cited By (378)

Papers in Blossom that reference this study

Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes

Stellmacher, J., Schmidt, C., Aicher, H. D. et al. · Frontiers in Psychiatry (2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research

O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)

Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial

Johnson, M. W., Naudé, G. P., Hendricks, P. S. et al. · JAMA Network Open (2026)

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression

Roberts, C., Seynaeve, M., Ermakova, A. O. et al. · Journal of Psychopharmacology (2026)

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)

12 cited
The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures

Scholle, P., Wenke, Š., Nekovářová, T. et al. · Journal of Psychopharmacology (2026)

Time-resolved Neural and Experience Dynamics of Medium- and High-dose N,N-Dimethyltryptamine

Lewis-Healey, E., Pallavicini, C., Cavanna, F. et al. · Journal of Cognitive Neuroscience (2025)

Show all 378 papers
A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Brett, J., Lea, T., Knock, E. et al. · Addiction (2025)

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial

Marsden, J., Kelleher, M., Dunbar, F. et al. · Addiction (2025)

28 cited
The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression

Beaussant, Y., Tarbi, E., Nigam, K. B. et al. · General Hospital Psychiatry (2025)

A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

Marek, G. J., Makai-Bölöni, S., Umbricht, D. et al. · Journal of Psychopharmacology (2025)

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

Knock, E., Siefried, K. J., Gill Bedi, |. et al. · Addiction (2025)

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial

Ross, M. L., Iyer, R., Williams, M. L. et al. · General Hospital Psychiatry (2025)

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D. et al. · Frontiers in Psychiatry (2025)

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial

Henry, J., Giribaldi, B., Nutt, D. J. et al. · European Neuropsychopharmacology (2025)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study

Ludbrook, G., Bryson, N., Taylor, B. et al. · Journal of Clinical Psychopharmacology (2025)

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception

Muller, S., Cavanna, F., de la Fuente, L. A. et al. · Scientific Reports (2025)

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Kato, K., Kleinhenz, J. M., Shin, Y. J. et al. · npj Aging (2025)

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial

Wießner, I., Falchi-Carvalho, M., Laborde, S. et al. · European Neuropsychopharmacology (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial

Zuiker, R. G. J. A., Otto, M. E., Bryan, C. S. et al. · Clinical and Translational Science (2025)

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I. et al. · Neuropsychopharmacology (2025)

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)

10 cited
Participant experiences of therapeutic touch in psilocybin-assisted therapy

Ham, R., Gardner, J., Carter, A. et al. · Brain and Behavior (2025)

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2025)

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder

Meshkat, S., Kaczmarek, E., Doyle, Z. et al. · Psychedelic Medicine (2025)

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)

Zeifman, R. J., Spriggs, M. J., Kettner, H. et al. · Scientific Reports (2025)

24 cited
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

Kirlic, N., Lennard-Jones, M., Atli, M. et al. · American Journal of Psychiatry (2025)

Practical considerations in the establishment of psychedelic research programs

Murnane, K. S., Barnett, B. S., Vest, •. M. F. et al. · Psychopharmacology (2024)

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)

84 cited
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

Stroud, J., Rice, C., Orsini, A. et al. · Psychopharmacology (2024)

Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being

Bonnelle, V., Feilding, A., Rosas, F. E. et al. · Journal of Psychopharmacology (2024)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Nicholas, C. R., Banks, M. I., Lennertz, R. L. et al. · Translational Psychiatry (2024)

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants

Vizeli, P., Studerus, E., Holze, F. et al. · Translational Psychiatry (2024)

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

Salvetti, G., Saccenti, D., Moro, A. S. et al. · Brain Sciences (2024)

Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation

Van Dongen, N. N. N., Zijlmans, J., Vermetten, E. et al. · European Journal of Psychotraumatology (2024)

Do classic psychedelics increase the risk of seizures? A scoping review

Soto-Angona, Ó., Fortea, A., Fortea, L. et al. · European Neuropsychopharmacology (2024)

Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields

Pais, M., Teixeira, M., Soares, C. et al. · NeuroImage (2024)

8 cited
Psilocybin desynchronizes brain networks

Nicol, G. E. · Nature (2024)

160 cited
Neural Mechanisms of Resting-State Networks and the Amygdala underlying the Cognitive and Emotional Effects of Psilocybin

Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)

Adolescent Psychedelic Use and Psychotic or Manic Symptoms

Simonsson, O., Mosing, M. A., Osika, W. et al. · JAMA Psychiatry (2024)

24 cited
Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)

Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression

Meling, D., Ehrenkra, R., Nayak, S. et al. · Psychoactives (2024)

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants

Rucker, J., Roberts, C. A., Seynaeve, M. et al. · Journal of Psychopharmacology (2024)

20 cited
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)

48 cited
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)

Psychiatric risks for worsened mental health after psychedelic use

Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)

41 cited
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey

Barnett, B. S., Arakelian, M., Beebe, D. et al. · Psychedelic Medicine (2024)

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

Rosenblat, J. D., Meshkat, S., Doyle, Z. et al. · Med (2024)

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial

Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)

18 cited
Psychedelics-assisted psychotherapy: Experiences with the limited medical use of LSD, MDMA, and psilocybin in Switzerland

Aicher, H. D., Schmid, Y., Gasser, P. · Die Psychotherapie (2024)

16 cited
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · Scientific Reports (2024)

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

Sandbrink, J. D., Johnson, K., Gill, M. et al. · AJOB Neuroscience (2024)

10 cited
Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

Effects of external stimulation on psychedelic state neurodynamics

Mediano, P. A. M., Rosas, F. E., Timmermann, C. et al. · ACS Chemical Neuroscience (2024)

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

James, E., Erritzoe, D., Benway, T. et al. · Frontiers in Psychiatry (2024)

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)

24 cited
Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis

Peacock, C., Mascaro, J. S., Brauer, E. et al. · PLOS ONE (2024)

21 cited
Safety pharmacology of acute psilocybin administration in healthy participants

Straumann, I., Holze, F., Becker, A. M. et al. · Neuroscience Applied (2024)

15 cited
Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

Agrawal, M., Richards, B. D., Richards, W. A. et al. · Cancer (2023)

Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)

10 cited
Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings

Nicholas, C. R., Horton, D. M., Malicki, J. et al. · Psychedelic Medicine (2023)

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers

Mathai, D. S., Hilbert, S., Sepeda, N. D. et al. · Psychedelic Medicine (2023)

6 cited
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)

Extended difficulties following the use of psychedelic drugs: A mixed methods study

Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)

123 cited
Psychedelic use and psychiatric risks

Simonsson, O., Goldberg, S. B., Chambers, R. et al. · Psychopharmacology (2023)

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression

Rodgers, A., Bahceci, D., Davey, C. G. et al. · Australian and new-zealand Journal of Psychiatry (2023)

5 cited
Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists

Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)

The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression

Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)

Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program

Manson, E., Ryding, E., Taylor, W. et al. · Journal of Psychoactive Drugs (2023)

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)

375 cited
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer

Lewis, B. R., Garland, E. L., Byrne, K. et al. · Journal of Pain and Symptom Management (2023)

49 cited
Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis

Nikolič, M., Viktorin, V., Zach, P. et al. · European Neuropsychopharmacology (2023)

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

Boehnke, K. F., Cox, K., Weston, C. et al. · Frontiers in Psychiatry (2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)

47 cited
The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada

Glynos, N., Kruger, D. J., Kolbman, N. et al. · Journal of Psychoactive Drugs (2023)

9 cited
Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Harnessing placebo: Lessons from psychedelic science

Pronovost-Morgan, C., Hartogsohn, I., Ramaekers, J. G. · Journal of Psychopharmacology (2023)

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial

Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)

Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca

Weiss, B., Wingert, A., Erritzoe, D. et al. · Scientific Reports (2023)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline

Pleet, M. M., White, J., Zamaria, J. A. et al. · Psychedelic Medicine (2023)

Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia

Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)

17 cited
Changed Substance Use After Psychedelic Experiences Among Individuals in Canada

Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)

11 cited
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)

4 cited
Self-reported effects of classic psychedelics on stuttering

Gold, N. D., Goldway, N., Gerlach-Houck, H. et al. · Biorxiv (2023)

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)

An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study

Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice

Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals

Wießner, I., Falchi, M., Daldegan-Bueno, D. et al. · European Neuropsychopharmacology (2023)

4 cited
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample

Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)

The therapeutic potential of psychedelics: the European regulatory perspective

Butlen-Ducuing, F., McCulloch, D. E-W., Haberkamp, M. et al. · Lancet (2023)

Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine

Mathai, D. S., Nayak, S., Yaden, D. B. et al. · Psychopharmacology (2023)

29 cited
A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics

Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)

Psilocybin-assisted therapy mediates psycho-social-spiritual change in cancer patients as assessed by the NIH-HEALS

Shnayder, S., Ameli, R., Sinaii, N. et al. · Journal of Affective Disorders (2023)

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)

Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use

Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

Forstmann, M., Kettner, H. S., Sagioglou, C. et al. · Journal of Psychopharmacology (2023)

Application of machine learning and complex network measures to an EEG dataset from ayahuasca experiments

Alves, C. L., Cury, R. G., Roster, K. et al. · PLOS ONE (2022)

Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Ledwos, N., Rodas, J. D., Husain, M. I. et al. · Journal of Psychopharmacology (2022)

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Desai, S., Jain, V., Xavier, S. et al. · Children (2022)

5 cited
Psychedelic Identity Shift: A Critical Approach to Set And Setting

Devenot, N., Seale-Feldman, A., Smith, E. et al. · Kennedy Institute of Ethics Journal (2022)

28 cited
Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT-A retrospective case study

Turkia, M. · Psychiatry Research (2022)

Therapeutic use of psilocybin: Practical considerations for dosing and administration

MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)

Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences

Rodríguez-Cano, B. J., Kohek, M., Ona, G. et al. · Drug and Alcohol Review (2022)

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression

Wall, M., Nutt, D. J., Kaelen, M. et al. · Journal of Psychopharmacology (2022)

23 cited
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study

Breeksema, J. J., Niemeijer, A. R., Kuin, B. et al. · Frontiers in Psychiatry (2022)

Psychedelic-Assisted Therapy for People with Eating Disorders

Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)

A Psychoanalytic Perspective on Psychedelic Experience

Guss, J. · Psychoanalytic Dialogues (2022)

Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)

Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience

Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)

35 cited
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis

Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)

Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

Kaypak, A. C., Raz, A. · Transcultural Psychiatry (2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Henningfield, J. E., Coe, M. A., Griffiths, R. R. et al. · Neuropharmacology (2022)

Naturalistic Psychedelic Use: A World Apart from Clinical Care

Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)

46 cited
Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex

Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)

A Dose of Creativity: An Integrative Review of the Effects of Serotonergic Psychedelics on Creativity

Costa, M. A. · Journal of Psychoactive Drugs (2022)

The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users

Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M. et al. · Frontiers in Psychology (2022)

Opening to Awe: Psychedelic-Assisted Self-Transcendence and Positive Adult Development

Arnaud, K. O. S., Sharpe. D. · Journal of Adult Development (2022)

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation

Johnson, M. W. · Current Topics in Behavioral Neurosciences (2022)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Self-Actualization and the Integration of Psychedelic Experience: The Mediating Role of Perceived Benefits to Narrative Self-Functioning

Amada, N., Shane, J. · Journal of Humanistic Psychology (2022)

Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model

Belser, A. B. · Frontiers in Psychology (2022)

57 cited
Postpartum depression: A role for psychedelics?

Jairaj, C., Rucker, J. · Journal of Psychopharmacology (2022)

New insights into the clinical and nonclinical effects of psychedelic substances: An integrative review.

Forstmann, M., Sagioglou, C. · European Psychologist (2022)

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations

Ortiz, C. E., Dourron, H. M., Sweat, N. W. et al. · Neuropharmacology (2022)

Pharmacokinetics of N,N-dimethyltryptamine in Humans

Good, M., Joel, Z., Benway, T. et al. · European Journal of Pharmacology (2022)

Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention and treatment

Doyle, M. A., Ling, S., Lui, L. M. W. et al. · Expert Opinion on Drug Safety (2022)

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)

Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns

Earleywine, M., Low, F., Lau, C. et al. · Journal of Humanistic Psychology (2022)

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)

162 cited
Psilocybin-Assisted Compassion Focused Therapy for Depression

Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)

Predictors and potentiators of psychedelic-occasioned mystical experiences

Gandy, S. · Journal of Psychedelic Studies (2022)

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations

Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)

95 cited
Disintegrating and Reintegrating the Self - (In)Flexible Self-Models in Depersonalisation and Psychedelic Experiences

Ciauncia, A., Safron, A. · Psyarxiv (2022)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

Family, N., Hendricks, P. S., Williams, L. T. J. et al. · Journal of Psychopharmacology (2022)

Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers

Thal, S., Engels, L. B., Bright, S. J. · Journal of Humanistic Psychology (2022)

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy

Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)

19 cited
Psilocybin induces spatially constrained alterations in thalamic functional organization and connectivity

Gaddis, A., Lidstone, D. E., Nebel, M. B. et al. · Biorxiv (2022)

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study

Jones, G. M., Nock, M. K. · Scientific Reports (2022)

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)

306 cited
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

Yu, C. L., Liang, C. S., Yang, F. et al. · Journal of Clinical Medicine (2022)

Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature

Golden, T. L., Magsamen, S., Sandu, C. C. et al. · Current Topics in Behavioral Neurosciences (2022)

Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy

Vargas-Perez, H., Grieder, T. E., Van Der Kooy, D. · Journal of Psychoactive Drugs (2022)

LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking

Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)

32 cited
Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants

Müller, F., Holze, F., Becker, A. M. et al. · Psychopharmacology (2022)

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation

Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)

Human behavioral pharmacology of psychedelics

Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)

5 cited
Effective Connectivity of LSD-induced Ego Dissolution

Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)

4 cited
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Toward a positive psychology of psychoactive drug use

Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2021)

5 cited
Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)

41 cited
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

Rucker, J., Jafari, H., Mantingh, T. et al. · BMJ Open (2021)

Recreational Psychedelic Users Frequently Encounter Complete Mystical Experiences: Trip Content and Implications for Wellbeing

Qiu, X., Minda, J. P. · Psyarxiv (2021)

5 cited
The readiness of psychiatrists to implement psychedelic-assisted psychotherapy

Page, L., Rehman, A., Syed, H. et al. · Frontiers in Psychiatry (2021)

30 cited
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review

Keeler, J. L., Treasure, J., Juruena, M. F. et al. · Nutrients (2021)

Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms

Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

Williams, M. L., Korevaar, D., Harvey, R. et al. · Frontiers in Psychiatry (2021)

16 cited
Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow

Maia, L. O., Feilding, A., Ribeiro, S. et al. · Psychopharmacology (2021)

A narrative synthesis of research with 5-MeO-DMT

Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)

Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample

Lafrance, A., Strahan, E., Bird, B. M. et al. · Journal of Humanistic Psychology (2021)

19 cited
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy

Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)

Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes

Matzopoulos, R., Morlock, A., Morlock, R. et al. · MedRvix (2021)

A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing

Brennan, W., Jackson, M. A., MacLean, K. A. · Journal of Humanistic Psychology (2021)

34 cited
Safety pharmacology of acute LSD administration in healthy subjects

Holze, F., Caluori, T. V., Vizeli, P. et al. · Psychopharmacology (2021)

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States

Davis, A. K., Agin-Liebes, G. I., España, M. et al. · Journal of Psychoactive Drugs (2021)

Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey

Barnett, B. S., Beaussant, Y., King, K. et al. · Journal of Psychoactive Drugs (2021)

This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders

Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J. et al. · Frontiers in Psychiatry (2021)

Effects of ayahuasca on personality: results of two randomized, placebo-controlled trials in healthy volunteers

Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)

Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation

Reynolds, L. M, Stack, A., Akroyd, A., Sundram, F. et al. · International Journal of Environmental Research and Public Health (2021)

22 cited
A Nationwide Study Comparing Mental Health Professionals' Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice

Ginati, Y. D., Ben-Sheetrit, J., Lev-Ran, S. et al. · Journal of Psychoactive Drugs (2021)

5 cited
Psychedelic drug use and schizotypy in young adults

Lebedev, A. V., Acar, K., Garzón, B. et al. · Scientific Reports (2021)

2 cited
Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)

Does psychedelic therapy have a transdiagnostic action and prophylactic potential?

Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)

73 cited
Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions

Mayer, C. E., LeBaron, V. T., Acquaviva, K. D. · Journal of Psychoactive Drugs (2021)

12 cited
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model

Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)

Research abuses against people of colour and other vulnerable groups in early psychedelic research

Strauss, D., de la Salle, S., Sloshower, J. A. et al. · Journal of Medical Ethics (2021)

Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial

Dos Santos, R. G., Osório, F. L., Rocha, J. M. et al. · Journal of Clinical Psychopharmacology (2021)

58 cited
An Encounter with the Other: A Thematic Analysis of Accounts of DMT Experiences from a Naturalistic Field Study

Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2021)

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)

Psychedelics and health behaviour change

Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Yockey, R. A., King, K. A. · Journal of Psychedelic Studies (2021)

Set and Setting in the Santo Daime

Hartogsohn, I. · Frontiers in Pharmacology (2021)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial

Rocha, J. M., Rossi, G. N., de Lima Osório, F. et al. · Journal of Clinical Psychopharmacology (2021)

37 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Ethical and legal issues in psychedelic harm reduction and integration therapy

Pilecki, B., Luoma, J. B., Bathje, G. J. et al. · Harm Reduction Journal (2021)

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies

Gard, D. E., Pleet, M. M., Bradley, E. R. et al. · Journal of Affective Disorders (2021)

Examining changes in personality following shamanic ceremonial use of ayahuasca

Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)

53 cited
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice

Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)

55 cited
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

Baseline power of theta oscillations predicts mystical-type experiences induced by DMT in a natural setting

Tagliazucchi, E., Zamberlan, F., Cavanna, F. et al. · Frontiers in Psychiatry (2021)

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

Zeifman, R. J., Singhal, N., Breslow, L. et al. · ACS Pharmacology and Translational Science (2021)

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects

Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)

Dose-response relationships of psilocybin-induced subjective experiences in humans

Hirschfeld, T., Schmidt, T. T. · Journal of Psychopharmacology (2021)

Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports

Nayak, S., Gukasyan, N., Barrett, F. S. et al. · Pharmacopsychiatry (2021)

Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings

Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research

Nielson, E. M., Tai, S. J., Lennard-Jones, M. et al. · Frontiers in Psychiatry (2021)

75 cited
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

112 cited
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)

Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine

Johnson, M. W. · ACS Pharmacology and Translational Science (2020)

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial

Rothberg, R. L., Azhari, N., Haug, N. A. et al. · Journal of Psychopharmacology (2020)

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants

Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review

DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)

Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans

Stenbæk, D. S., Madsen, M. K., Ozenne, B. et al. · Journal of Psychopharmacology (2020)

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study

Anderson, B. T., Danforth, A. L., Daroff, R. et al. · EClinicalMedicine (2020)

212 cited
Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention

Barrett, F. S., Krimmel, S. R., Griffiths, R. R. et al. · NeuroImage (2020)

Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials

Vargas, A. S., Luís, Â., Barroso, M. et al. · Biomedicines (2020)

The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)

A potential role for psilocybin in the treatment of obsessive-compulsive disorder

Jacobs, E. · Journal of Psychedelic Studies (2020)

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Updating the dynamic framework of thought: Creativity and psychedelics

Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)

Compassionate use of psychedelics

Greif, A., Šurkala, M. · Medicine Health Care and Philosophy (2020)

Ethics and ego dissolution: the case of psilocybin

Smith, W. R., Sisti, D. · Journal of Medical Ethics (2020)

Psychedelic treatment of functional neurological disorder: a systematic review

Butler, M., Seynaeve, M., Nicholson, T. R. et al. · Therapeutic Advances in Psychopharmacology (2020)

Chronic pain and psychedelics: a review and proposed mechanism of action

Castellanos, J. P., Woolley, C., Bruno, K. A. et al. · Regional Anesthesia and Pain Medicine (2020)

101 cited
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)

73 cited
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review

Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)

63 cited
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

Lancelotta, R., Davis, A. K. · Journal of Psychoactive Drugs (2020)

Tripping on nothing: placebo psychedelics and contextual factors

Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M. et al. · Psychopharmacology (2020)

Self-reported negative outcomes of psilocybin users: A quantitative textual analysis

Bienemann, B., Ruschel, N. S., Campos, M. L. et al. · PLOS ONE (2020)

57 cited
Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)

121 cited
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

Classic psychedelics as therapeutics for psychiatric disorders

Nichols, C. D., Hendricks, P. S. · Handbook of Behavioral Neuroscience (2020)

Neuropharmacological modulation of the aberrant bodily self through psychedelics

Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms

Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner

Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)

131 cited
The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial.

Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F. et al. · Frontiers in Pharmacology (2019)

96 cited
Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science

Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Felix, M., Stefan, B. · Swiss Medical Weekly (2019)

Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects

Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)

Psychedelic microdosing benefits and challenges: an empirical codebook

Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT

Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)

171 cited
Psychedelic-Assisted Group Therapy: A Systematic Review

Trope, A., Anderson, B. T., Hooker, A. R. et al. · Journal of Psychoactive Drugs (2019)

States and traits related to the quality and consequences of psychedelic experiences

Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)

Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers

Erritzoe, D., Smith, J. M., Fisher, P. M. et al. · Journal of Psychopharmacology (2019)

Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users

Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

Psychiatry might need some psychedelic therapy

Johnson, M. W. · International Review of Psychiatry (2018)

An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders

Renelli, M., Fletcher, J., Tupper, K. W. et al. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity (2018)

68 cited
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study

Dakwar, E., Nunes, E. V., Hart, C. L. et al. · Neuropharmacology (2018)

72 cited
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy

Hendricks, P. S. · International Review of Psychiatry (2018)

143 cited
Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

DMT models the near-death experience

Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)

Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress

Ross, S. · International Review of Psychiatry (2018)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition

Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)

78 cited
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Schenberg, E. E. · Frontiers in Pharmacology (2018)

High dose psilocybin is associated with positive subjective effects in healthy volunteers

Nicholas, C. R., Henriquez, K. M., Gassman, M. C. et al. · Journal of Psychopharmacology (2018)

61 cited
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

Effects of psilocybin therapy on personality structure

Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)

219 cited
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic

Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)

The Use of Salvia divinorum from a Mazatec Perspective

Maqueda, A. E. · Plant Medicines Healing and Psychedelic Science (2018)

Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology

Moroz, M., Carhart-Harris, R. L. · IEEE Explore (2018)

6 cited
Psychedelics: Where we are now, why we got here, what we must do

Belouin, S. J., Henningfield, J. E. · Neuropharmacology (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers

Bravermanová, A., Viktorinová, M., Tylš, F. et al. · Psychopharmacology (2018)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD

Atasoy, S., Leor, R., Kaelen, M. et al. · Scientific Reports (2017)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)

102 cited
Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Stroud, J., Freeman, T. P., Leech, R. et al. · Psychopharmacology (2017)

88 cited
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)

393 cited
Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited
Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music

Barrett, F. S., Preller, K. H., Herdener, M. et al. · Cerebral Cortex (2017)

Long-lasting subjective effects of LSD in normal subjects

Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)

Serotonin and brain function: a tale of two receptors

Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)

Dreams and psychedelics: neurophenomenological comparison and therapeutic implications

Kraehenmann, R. · Current Neuropharmacology (2017)

68 cited
Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions

Slevc, L. R., Barrett, F. S., Robbins, H. et al. · Frontiers in Psychology (2017)

LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark

Larsen, J. K. · Nordic Journal of Psychiatry (2017)

Developing Guidelines and Competencies for the Training of Psychedelic Therapists

Phelps, J. · Journal of Humanistic Psychology (2017)

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness

Forstmann, M., Sagioglou, C. · Journal of Psychopharmacology (2017)

134 cited
Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation

Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)

138 cited
The psychological and human brain effects of music in combination with psychedelic drugs

Kaelen, M. · Imperial College London (2017)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)

The association of psychedelic use and opioid use disorders among illicit users in the United States

Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance

Dinis-Oliveira, R. J. · Drug Metabolism Reviews (2017)

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)

117 cited
Constructing drug effects: a history of set and setting

Hartogsohn, I. · Drug Science Policy and Law (2017)

389 cited
Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Rucker, J., Young, A. H., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)

Psychedelics as Medicines: An Emerging New Paradigm

Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)

Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)

The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving

Sweat, N. W., Bates, L. W., Hendricks, P. S. · Journal of Psychoactive Drugs (2016)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Psilocybin for treating substance use disorders?

de Veen, B. T. H., Schellekens, A., Verheij, M. M. et al. · Expert Review of Neurotherapeutics (2016)

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
A Public-Health-Based Vision for the Management and Regulation of Psychedelics

Haden, M., Emerson, B., Tupper, K. W. · Journal of Psychoactive Drugs (2016)

28 cited
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

LSD-induced entropic brain activity predicts subsequent personality change

Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)

292 cited
Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use

Walsh, Z., Hendricks, P. S., Smith, S. et al. · Journal of Psychopharmacology (2016)

58 cited
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects

Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)

253 cited
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Psychedelic medicine: a re-emerging therapeutic paradigm

Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Acute Biphasic Effects of Ayahuasca

Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)

101 cited
LSD enhances the emotional response to music

Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)

Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)

420 cited
A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment

Nutt, D. J., Carhart-Harris, R. L. · Current Drug Abuse Reviews (2015)

50 cited
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca

Winkelman, M. J. · Current Drug Abuse Reviews (2014)

Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia

Winkler, P., Csémy, L. · Journal of Psychoactive Drugs (2014)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Therapeutic infusions of ketamine: do the psychoactive effects matter?

Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)

89 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

Ayahuasca and cancer treatment

Schenberg, E. E. · Sage Open Medicine (2013)

Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin

Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)

Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer

Grob, C. S., Bossis, A. P., Griffiths, R. R. · Preprints (2013)

Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)

Health status of ayahuasca users

Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses

Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)

Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

Johnson, M. W., Maclean, K. A., Reissig, C. J. et al. · Drug and Alcohol Dependence (2011)

132 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

423 cited
Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Carhart-Harris, R. L., Nutt, D. J. · Journal of Substance Use (2010)

The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability

Carhart-Harris, R. L., Williams, T. M., Sessa, B. et al. · Journal of Psychopharmacology (2010)

The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas

Carhart-Harris, R. L., Friston, K. J. · Brain (2010)

492 cited
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R. R. · Journal of Psychopharmacology (2008)

The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin

Richards, W. A. · Archive for the Psychology of Religion (2008)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in